You are here

  • Home
  • Archive
  • Volume 10, Issue 4
  • Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

Citation Tools

Article menu
Clinical/translational cancer immunotherapy
Original research
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Aggarwal C, Prawira A, Antonia S, et al
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
Journal for ImmunoTherapy of Cancer 2022;10:e004424. doi: 10.1136/jitc-2021-004424